Limits...
Clinical significance of nuclear factor κB and chemokine receptor CXCR4 expression in patients with diffuse large B-cell lymphoma who received rituximab-based therapy.

Shin HC, Seo J, Kang BW, Moon JH, Chae YS, Lee SJ, Lee YJ, Han S, Seo SK, Kim JG, Sohn SK, Park TI - Korean J. Intern. Med. (2014)

Bottom Line: High NF-κB expression was associated with CXCR4 expression (p = 0.002), and 56 patients (80.0%) showed coexpression.However, the expression of NF-κB or CXCR4 was not associated with overall survival and EFS.On multivariate analysis that included age, gender, performance status, stage, and the IPI, no significant association between the grade of NF-κB or CXCR4 expression and survival was observed.

View Article: PubMed Central - PubMed

Affiliation: Department of Hematology and Oncology, Kyungpook National University Hospital, Daegu, Korea.

ABSTRACT

Background/aims: This study investigated the expression of nuclear factor κB (NF-κB) and the chemokine receptor (CXCR4) in patients with diffuse large B-cell lymphoma (DLBCL) who received rituximab-based therapy.

Methods: Seventy patients with DLBCL and treated with rituximab-CHOP (R-CHOP) were included, and immunohistochemistry was performed to determine the expression of NF-κB (IκB kinase α, p50, and p100/p52) and CXCR4. To classify DLBCL cases as germinal center B-cell-like (GCB) and non-GCB, additional immunohistochemical expression of CD10, bcl-6, or MUM1 was used in this study. The expression was divided into two groups according to the intensity score (negative, 0 or 1+; positive, 2+ or 3+).

Results: The median age of the patients was 66 years (range, 17 to 87), and 58.6% were male. Twenty-seven patients (38.6%) had stage III or IV disease at diagnosis. Twenty-three patients (32.9%) were categorized as high or high-intermediate risk according to their International Prognostic Indexs (IPIs). The overall incidence of bone marrow involvement was 5.7%. Rates of positive NF-κB and CXCR4 expression were 84.2% and 88.6%, respectively. High NF-κB expression was associated with CXCR4 expression (p = 0.002), and 56 patients (80.0%) showed coexpression. However, the expression of NF-κB or CXCR4 was not associated with overall survival and EFS. On multivariate analysis that included age, gender, performance status, stage, and the IPI, no significant association between the grade of NF-κB or CXCR4 expression and survival was observed.

Conclusions: The current study suggests that the tissue expression of NF-κB and CXCR4 may not be an independent prognostic marker in DLBCL patients treated with R-CHOP.

Show MeSH

Related in: MedlinePlus

Representative examples of immunohistochemical staining with (A) anti-nuclear factor κB (anti-NF-κB) p100/p52, (B) NF-κB p50, (C) IκB kinase α, and (D) CXCR4 antibodies (×400).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4219968&req=5

Figure 1: Representative examples of immunohistochemical staining with (A) anti-nuclear factor κB (anti-NF-κB) p100/p52, (B) NF-κB p50, (C) IκB kinase α, and (D) CXCR4 antibodies (×400).

Mentions: The NF-κB and CXCR4 expression results are shown in Fig. 1. Positive NF-κB expression was found in 59 patients (84.3%) and CXCR4 in 62 patients (88.6%). Regarding the NF-κB and CXCR4 statuses, no significant difference was found between the GCB and non-GCB groups. High NF-κB expression was associated with CXCR4 expression (p = 0.002), and 56 patients (80.0%) showed coexpression (Table 2). With a median follow-up duration of 24.7 months (range, 0.3 to 66.4) among the patients alive at the last follow up, the 5-year OS and EFS rates were 80.0% and 73.7%, respectively. The expression of NF-κB or CXCR4 was not associated with OS or EFS (Fig. 2). On multivariate analysis that included age, gender, performance status, stage, and IPI, no significant association was observed between the grade of NF-κB or CXCR4 expression and survival. The IPI and older age were independent prognostic factors of OS for patients with DLBCL (Table 3).


Clinical significance of nuclear factor κB and chemokine receptor CXCR4 expression in patients with diffuse large B-cell lymphoma who received rituximab-based therapy.

Shin HC, Seo J, Kang BW, Moon JH, Chae YS, Lee SJ, Lee YJ, Han S, Seo SK, Kim JG, Sohn SK, Park TI - Korean J. Intern. Med. (2014)

Representative examples of immunohistochemical staining with (A) anti-nuclear factor κB (anti-NF-κB) p100/p52, (B) NF-κB p50, (C) IκB kinase α, and (D) CXCR4 antibodies (×400).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4219968&req=5

Figure 1: Representative examples of immunohistochemical staining with (A) anti-nuclear factor κB (anti-NF-κB) p100/p52, (B) NF-κB p50, (C) IκB kinase α, and (D) CXCR4 antibodies (×400).
Mentions: The NF-κB and CXCR4 expression results are shown in Fig. 1. Positive NF-κB expression was found in 59 patients (84.3%) and CXCR4 in 62 patients (88.6%). Regarding the NF-κB and CXCR4 statuses, no significant difference was found between the GCB and non-GCB groups. High NF-κB expression was associated with CXCR4 expression (p = 0.002), and 56 patients (80.0%) showed coexpression (Table 2). With a median follow-up duration of 24.7 months (range, 0.3 to 66.4) among the patients alive at the last follow up, the 5-year OS and EFS rates were 80.0% and 73.7%, respectively. The expression of NF-κB or CXCR4 was not associated with OS or EFS (Fig. 2). On multivariate analysis that included age, gender, performance status, stage, and IPI, no significant association was observed between the grade of NF-κB or CXCR4 expression and survival. The IPI and older age were independent prognostic factors of OS for patients with DLBCL (Table 3).

Bottom Line: High NF-κB expression was associated with CXCR4 expression (p = 0.002), and 56 patients (80.0%) showed coexpression.However, the expression of NF-κB or CXCR4 was not associated with overall survival and EFS.On multivariate analysis that included age, gender, performance status, stage, and the IPI, no significant association between the grade of NF-κB or CXCR4 expression and survival was observed.

View Article: PubMed Central - PubMed

Affiliation: Department of Hematology and Oncology, Kyungpook National University Hospital, Daegu, Korea.

ABSTRACT

Background/aims: This study investigated the expression of nuclear factor κB (NF-κB) and the chemokine receptor (CXCR4) in patients with diffuse large B-cell lymphoma (DLBCL) who received rituximab-based therapy.

Methods: Seventy patients with DLBCL and treated with rituximab-CHOP (R-CHOP) were included, and immunohistochemistry was performed to determine the expression of NF-κB (IκB kinase α, p50, and p100/p52) and CXCR4. To classify DLBCL cases as germinal center B-cell-like (GCB) and non-GCB, additional immunohistochemical expression of CD10, bcl-6, or MUM1 was used in this study. The expression was divided into two groups according to the intensity score (negative, 0 or 1+; positive, 2+ or 3+).

Results: The median age of the patients was 66 years (range, 17 to 87), and 58.6% were male. Twenty-seven patients (38.6%) had stage III or IV disease at diagnosis. Twenty-three patients (32.9%) were categorized as high or high-intermediate risk according to their International Prognostic Indexs (IPIs). The overall incidence of bone marrow involvement was 5.7%. Rates of positive NF-κB and CXCR4 expression were 84.2% and 88.6%, respectively. High NF-κB expression was associated with CXCR4 expression (p = 0.002), and 56 patients (80.0%) showed coexpression. However, the expression of NF-κB or CXCR4 was not associated with overall survival and EFS. On multivariate analysis that included age, gender, performance status, stage, and the IPI, no significant association between the grade of NF-κB or CXCR4 expression and survival was observed.

Conclusions: The current study suggests that the tissue expression of NF-κB and CXCR4 may not be an independent prognostic marker in DLBCL patients treated with R-CHOP.

Show MeSH
Related in: MedlinePlus